Loading data for CRMD — first visit, this takes a few seconds.
CorMedix Inc. (CRMD)
NasdaqGM: CRMD
· Real-Time Price · USD
8.20
-0.03 (-0.36%)
At close: Aug 21, 2026, 8:00 PM
8.20
+0.00%
After-hours: 7:56 PM
The price, the headline numbers and the latest news, in one place.
CorMedix Inc. (CRMD) Stock Price, Analysis & Data
-0.36% (1D)
No data available
| Bid | 5.35 |
| Market Cap | 639.14M |
| Revenue (ttm) | 462.25M |
| Net Income (ttm) | 186.02M |
| 1.50 | |
| 2.18 | |
| 3.76 | |
| 23.43 | |
| P/B (ttm) | 1.38 |
| P/S (ttm) | 1.38 |
| Earnings Date | Nov 16, 2026 |
| Ask | 9.71 |
| Volume | 1,473,258 |
| Avg. Volume (20D) | 1,326,137 |
| Open | 8.29 |
| Previous Close | 8.23 |
| Day's Range | 8.15 - 8.41 |
| 52-Week Range | 6.13 - 14.96 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to ...
Industry Biotechnology
Sector Healthcare
IPO Date May 13, 2010
Employees 191
Stock Exchange NasdaqGM
Ticker Symbol CRMD
Website https://cormedix.com
Financial Performance
In 2025, CorMedix's revenue was 311.71M, an increase of 617.03% compared to the previous year's 43.47M. Earnings were 163.06M, a decrease of -1,009.4%.
Financial StatementsEarnings Surprise
CorMedix has released their quarterly earnings on Aug 13, 2026:
- Revenue of $127.43M misses estimates by $0, with 226.05% YoY growth.
- EPS of 0.29 exceeds estimates by 0.05, with 3.57% YoY growth.
CorMedix Inc. is scheduled to release its earnings on Nov 16, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2